Research Funding

Open opportunities and active NIH grants in structural heart and prosthetic valves

Open Opportunities

1 active
Federal9d left

NHLBI Stimulating Peripheral Activity to Relieve Conditions (SPARC)

National Heart, Lung, and Blood Institute (NIH)

NHLBI funding opportunities for cardiovascular device development including transcatheter and surgical valve technologies.

Varies
Deadline: Dec 1, 2026
US investigators
View opportunity

Funded Research

1 active grants · $749K total

Filter by Topic

Clear filters

Data from NIH Reporter. Updated weekly.

R01FY2026Prosthetic
$749K
Mitigation Strategies for Metabolic Syndrome-induced Bioprosthetic Heart Valve Degeneration
FERRARI, GIOVANNI
ends Feb 28, 2029

SUMMARY Bioprosthetic heart valves (BHV), made from glutaraldehyde-fixed xenografts, are widely used for surgical (SAVR) and transcatheter valve interventions (TAVR), but suffer from limited durability due to Structural Valve Degeneration (SVD). Advances in BHV device engineering and delivery have created the possibility to provide state-of-the-art care to heart valve disease patients that were once deemed inoperable due to their risk score and advanced co-morbidities. However, the same class of devices is offered to all patients, irrespectively of their co-morbidities and susceptibility to structural valve degeneration. Metabolic syndrome (MetS) is a common comorbidity in patients who require BHV and is a known risk factor for cardiovascular diseases. Our published and preliminary results show the enhanced susceptibility of bio-implantable materials to oxidation, glycation, pro- calcific proteins, and crosslinkers in patients with Metabolic Syndrome or rodent model of MetS, using Zuck